http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2155612-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_db5d8ec25fbd443f8912686d62bea1ff http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d611a1efa633e0b605046d3f73246f54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f07b8869692c91c2bd0af963b4c36d53 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-235 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-166 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522 |
| filingDate | 1997-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2000-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad8eb30183a561bb1ee827c6a9a6e940 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e48e9497fb29585ab13715195cfea92f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb15b56d66bea2dd266b5d29d2bf313b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba79b7366f5fe2bb3466ce381f92bd49 |
| publicationDate | 2000-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2155612-C2 |
| titleOfInvention | Method for treating the cases of acute infectious diseases of peripheral nerve system |
| abstract | FIELD: medicine. SUBSTANCE: method involves applying complex therapy. Instenon is administered in addition depending on disease form. Severe generalized and ascending forms of diphtheric polyneuropathy and polyradiculoneuritis are administered at the beginning of the disease in intravenous dripping mode at a dose of 1 to 2.0 ml once a day depending on patient age during 5-10 days. Then the preparations are administered per os at a dose of 1/3 to 1 dragee 3 times a day depending on the degree the neurologic symptoms are marked. Facial nerve neuritis, or poliomyelitis and diphtheric polyneuropathy and polyradiculoneuritis of moderate severity degree being the case, Instenon is intramuscularly administered at a dose of 1 to 2.0 ml once a day during 5-10 days in acute period. Its following peroral administration during restitution and convalescence period is applied during 2-6 weeks. Poliomyelitis-like diseases and light cases of facial nerve neuritis, diphtheric polyneuropathy and polyradiculoneuritis being the case, Instenon is per os administered during 2-4 weeks in the first days of the disease in combination with Instenon electrophoresis on the area of injured segments. Its following administration as applications in convalescence period is prescribed when some residual phenomena are available. EFFECT: accelerated treatment course. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2528108-C2 |
| priorityDate | 1997-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 52.